These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21814024)
1. [RANKL signaling and bone diseases. Quiescent osteoclast precursors and RANKL signaling]. Mizoguchi T Clin Calcium; 2011 Aug; 21(8):1187-92. PubMed ID: 21814024 [TBL] [Abstract][Full Text] [Related]
2. Lineage-committed osteoclast precursors circulate in blood and settle down into bone. Muto A; Mizoguchi T; Udagawa N; Ito S; Kawahara I; Abiko Y; Arai A; Harada S; Kobayashi Y; Nakamichi Y; Penninger JM; Noguchi T; Takahashi N J Bone Miner Res; 2011 Dec; 26(12):2978-90. PubMed ID: 21898588 [TBL] [Abstract][Full Text] [Related]
3. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts. Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510 [TBL] [Abstract][Full Text] [Related]
4. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice. Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788 [TBL] [Abstract][Full Text] [Related]
5. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. Takahashi N; Muto A; Arai A; Mizoguchi T Adv Exp Med Biol; 2010; 658():21-30. PubMed ID: 19950012 [TBL] [Abstract][Full Text] [Related]
6. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
7. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376 [TBL] [Abstract][Full Text] [Related]
8. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644 [TBL] [Abstract][Full Text] [Related]
9. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833 [TBL] [Abstract][Full Text] [Related]
10. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway. Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169 [TBL] [Abstract][Full Text] [Related]
11. Impaired osteoclastogenesis by staphylococcal lipoteichoic acid through Toll-like receptor 2 with partial involvement of MyD88. Yang J; Ryu YH; Yun CH; Han SH J Leukoc Biol; 2009 Oct; 86(4):823-31. PubMed ID: 19602669 [TBL] [Abstract][Full Text] [Related]
13. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [TBL] [Abstract][Full Text] [Related]
14. Dual modulation of osteoclast differentiation by lipopolysaccharide. Zou W; Bar-Shavit Z J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834 [TBL] [Abstract][Full Text] [Related]
15. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054 [TBL] [Abstract][Full Text] [Related]
16. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673 [TBL] [Abstract][Full Text] [Related]
17. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Takahashi N; Udagawa N; Suda T Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918 [TBL] [Abstract][Full Text] [Related]
18. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200 [TBL] [Abstract][Full Text] [Related]
19. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta. Lari R; Fleetwood AJ; Kitchener PD; Cook AD; Pavasovic D; Hertzog PJ; Hamilton JA Bone; 2007 Feb; 40(2):323-36. PubMed ID: 17055352 [TBL] [Abstract][Full Text] [Related]
20. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. Kanazawa K; Kudo A J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]